📌 Is BSX a Buy right now?
According to Ultra Stock Analysis Pro, Boston Scientific Corporation (BSX) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are strong (P/E: 26.2, Revenue Growth: +11.6%), while short-term technicals show a bearish trend (RSI: 43). Consider waiting for support confirmation near $67.16 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open BSX Analysis ↗
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to BSX based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 45% of the time over a medium-term (months) hold period, with an average return of +7.1% per trade.
To assist with risk management, here are the three most probable paths for BSX over the next trading week:
🟢 The Bull Case (Probability: 20%)
If BSX reclaims the $67.16 resistance level (Bollinger Upper), algorithmic targets shift to $87.06. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $59.10 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $56.70 liquidity zone (-9.3% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 31 (strong trend), momentum suggests a directional move is imminent between $59.10 and $67.16 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $62.53 | Market Cap | $92.9B |
| Past Win Rate (Backtest) | 45.5% | Forward P/E | 16.6x |
| Past Total Return | +28.0% | Analyst Target | $87.06 |
| RSI / Trend Strength | 43 / 31 | Upside to Target | +39.2% |
| MACD Signal | Bearish | Revenue Growth | +11.6% |
| Profit Factor | 3.20 | Institutional Own. | 95.5% |
| Position Entry | 2026-04-09 @ $61.28 | Analyst Ratings | 33 Buy / 1 Hold / 0 Sell |
| Open Position Past P&L | +2.0% |
MAINTAIN POSITION - Current position showing 2.0% unrealized gain. Use intelligent stop loss strategy below.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Entry: $61.28 on 2026-04-09
Confluence: 5.0
Stop Loss: $57.73
Backtest Results (Since 2018):
Past Win Rate
45%
Past Total Return
+28.0%
Max Drawdown
-16.4%
Avg Trade
+7.1%
Trades
11
Adaptive ATR Stop Loss (1.0-2.75x)
Entry: $61.28 on 2026-04-09
Confluence: 5.0
Stop Loss: $58.93
Backtest Results (Since 2018):
Past Win Rate
56%
Past Total Return
+38.6%
Max Drawdown
-15.1%
Avg Trade
+10.6%
Trades
9
Current Price
$62.53
Buy Stop Loss
$57.73
Distance: 8%
Conservative 2.0x
Position Stop Loss
$57.73
Distance: 8%
Hybrid 2.00x
ATR 14 Day
$2.40
Volatility
ADX Strength
31.4
Strong trend
Position up +2% - Adaptive strategy adjusts for momentum
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
| Indicator | Value | Signal |
|---|---|---|
| EMA 20 | $64.22 | Bearish |
| EMA 50 | $69.52 | Bearish |
| RSI (14) | 43.3 | Neutral range |
| Trend Strength (ADX) | 31.4 | Strong trend (25-50) |
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| RBC Capital | REITERATED | Outperform → Outperform | Mar 30, 2026 |
| Raymond James | DOWNGRADE | Strong Buy → Outperform | Mar 30, 2026 |
| Needham | REITERATED | Buy → Buy | Mar 30, 2026 |
| Needham | REITERATED | Buy → Buy | Mar 20, 2026 |
| BTIG | REITERATED | Buy → Buy | Feb 09, 2026 |
| Average Target: | $87.06 | High Target: | $110.00 |
| Current Price: | $62.53 | Low Target: | $69.00 |
| Upside to Average: | +39.2% | Number of Analysts: | 31 |
Based on backtest performance (Win Rate: 45.5%, Avg Return: +7.1%) and analyst consensus (Target: $87.06, +39.2% upside), an OVERWEIGHT exposure may be considered. Risk/Reward ratio of 2.62:1 suggests favorable risk-adjusted returns. Current open position shows +2.0% unrealized gain.
Boston Scientific Corporation operates in the Healthcare sector (Medical Devices). Current valuation of 16.6x forward P/E reflects reasonable multiples relative to growth prospects. Operating margin of 21.5% shows strong profitability.
Fundamental Outlook: Steady Growth - Expanding margins with consistent revenue growth
Overall Score: 3.7/10 - Slightly Bullish
Analysts have trimmed their fair value estimate for Boston Scientific from US$100.31 to US$95.75, a reset that anchors the latest round of target upda...
Boston Scientific (NYSE:BSX) reported first-quarter 2026 results that landed near the top end of management’s prior guidance, while executives reduced...
Boston Scientific (NYSE:BSX) stock has taken a beating in 2026 after management cut full-year guidance on Wednesday. On Thursday, three major firms tr...
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 bil...
Texas Instruments upgraded, Avis downgraded: Wall Street's top analyst calls...
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
| Metric | Value |
|---|---|
| Market Cap | $92.9B |
| P/E Ratio (Forward) | 16.6 |
| EPS (Forward) | $3.78 |
| Dividend Yield | 0.00% |
| 52-Week Range | $59.39 - $109.50 |
| Beta | 0.78 |
| Avg Volume | 17.3M |
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $62.53 | Volume | 11.9M |
| EMA 20 | $64.22 | EMA 50 | $69.52 |
| EMA 200 | $85.08 | Current Price | $62.53 |
| RSI (14) | 43.30 | MACD | -1.735 |
| MACD Signal | -2.286 | MACD Histogram | 0.551 |
| Trend Strength (ADX) | 31.45 | Volatility (ATR 14) | $2.40 |
| Bollinger Upper | $67.16 | Bollinger Lower | $59.10 |
| Stochastic %K | 71.62 | Stochastic %D | 54.32 |
| VWAP | $63.63 | Bollinger Middle | $63.13 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $92.9B | Revenue | $20.6B |
| Forward P/E | 16.6 | Revenue Growth | +11.6% |
| Trailing P/E | 26.2 | Gross Margin | 68.6% |
| Price/Sales | 4.51 | Operating Margin | 21.5% |
| Price/Book | 3.83 | Profit Margin | 17.3% |
| PEG Ratio | 0.70 | ROE | 0.0% |
| Enterprise Value | $107.7B | Free Cash Flow | $0.0B |
Comprehensive Trading Performance and Position Details
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-04-09 | $61.28 | +2.04% | $57.00 |
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2019-11-19 | 2020-02-04 | $42.63 | $42.88 | +0.59% | Win |
| 2020-07-23 | 2020-10-22 | $38.43 | $36.86 | -4.09% | Loss |
| 2020-11-23 | 2021-01-08 | $33.33 | $36.75 | +10.26% | Win |
| 2021-04-21 | 2021-11-26 | $42.31 | $38.57 | -8.84% | Loss |
| 2022-01-03 | 2022-05-11 | $43.12 | $38.74 | -10.16% | Loss |
| 2022-08-02 | 2022-09-27 | $41.46 | $38.14 | -8.01% | Loss |
| 2022-11-30 | 2025-04-04 | $45.27 | $89.70 | +98.14% | Win |
| 2025-04-07 | 2025-09-17 | $91.54 | $98.50 | +7.60% | Win |
| 2025-11-13 | 2025-11-19 | $104.98 | $97.01 | -7.59% | Loss |
| 2026-03-12 | 2026-04-02 | $68.55 | $62.82 | -8.36% | Loss |
Summary: 11 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-04-24. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: April 24, 2026 at 12:28 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis